It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Healthy regeneration of tissue relies on a well-orchestrated release of growth factors. Herein, we show the use of synthetic glycosaminoglycans for controlled binding and release of growth factors to induce a desired cellular response. First, we screened glycosaminoglycans with growth factors of interest to determine kon (association rate constant), koff (dissociation rate constant), and Kd (equilibrium rate constant). As proof-of-concept, we functionalized an elastin-like recombinamer (ELR) hydrogel with a synthetic glycosaminoglycan and immobilized fibroblast growth factor 2 (FGF2), demonstrating that human umbilical vein endothelial cells cultured on top of ELR hydrogel differentiated into tube-like structures. Taking this concept further, we developed a tunable macroporous ELR cryogel material, containing a synthetic glycosaminoglycan and FGF2 that showed increased blood vessel formation and reduced immune response compared to control when implanted in a subcutaneous mouse model. These results demonstrated the possibility for specific release of desired growth factors in/from a modular 3D scaffold in vitro and in vivo.
Functionalization of a macroporous elastic-like recombinamer hydrogel with synthetic glycosaminoglycans enables controlled binding and release of growth factors for blood vessel formation with reduced immune response in a subcutaneous mouse model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Lund University, Lung Biology, Department of Experimental Medical Science, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
2 Lund University, Division Pure and Applied Biochemistry, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
3 Universidad de Valladolid, BIOFORGE Lab, CIBER-BBN, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329)
4 University of North Carolina, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Phamarcy, Chapel Hill, USA (GRID:grid.410711.2) (ISNI:0000 0001 1034 1720)